Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Eledon Pharmaceuticals (ELDN) Shares Outstanding (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Shares Outstanding readings, the most recent being $7.1 million for Q4 2017.

  • On a quarterly basis, Shares Outstanding fell 63.6% to $7.1 million in Q4 2017 year-over-year; TTM through Dec 2017 was $7.1 million, a 63.6% decrease, with the full-year FY2017 number at $7.1 million, down 63.6% from a year prior.
  • Shares Outstanding hit $7.1 million in Q4 2017 for Eledon Pharmaceuticals, up from $6.9 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $155.6 million in Q4 2013 to a low of $373259.0 in Q4 2015.
  • Median Shares Outstanding over the past 5 years was $22.4 million (2015), compared with a mean of $26.6 million.
  • Biggest five-year swings in Shares Outstanding: crashed 85.61% in 2014 and later grew 3.39% in 2015.
  • Eledon Pharmaceuticals' Shares Outstanding stood at $155.6 million in 2013, then plummeted by 85.61% to $22.4 million in 2014, then fell by 12.73% to $19.5 million in 2015, then changed by 0.0% to $19.5 million in 2016, then tumbled by 63.6% to $7.1 million in 2017.
  • The last three reported values for Shares Outstanding were $7.1 million (Q4 2017), $6.9 million (Q3 2017), and $6.9 million (Q2 2017) per Business Quant data.